An Exploratory, Single-center, Randomized, Open Label, Active-control, Cross-over Trial Comparing the Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart (Fiasp) Compared to NovoLog Used in the Medtronic 670G Closed Loop System in Adults With Type 1 Diabetes
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Insulin aspart (Primary) ; Insulin aspart (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
Most Recent Events
- 30 Apr 2020 Status changed from active, no longer recruiting to completed.
- 12 Feb 2020 Planned End Date changed from 1 Apr 2020 to 1 May 2020.
- 12 Feb 2020 Planned primary completion date changed from 1 Feb 2020 to 7 Apr 2020.